News > FDA nod for Pfizer COVID-19 boosters for seniors, high-risk but hurdles remain

FDA nod for Pfizer COVID-19 boosters for seniors, high-risk but hurdles remain

The FDA authorised booster doses for Americans who are 65 and older, younger adults with underlying health conditions and those in jobs that put them at high risk for COVID-19. The ruling represents a drastically scaled-back version of the Biden administration's sweeping plan to give third doses to nearly all American adults.

However, more regulatory hurdles lie ahead before the dispensing of boosters can begin.